Physician profile
John Michael Wallmark
NPI 1689755365
$7,285.11
in general payments reported to CMS, 2019-2025
37 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $8.08 · 2021: $11.92 · 2022: $99.70 · 2023: $787 · 2024: $2,630 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351 · Long Term Medical Supply Or Device Loan: $2,299 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.47 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $244.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,733.76 | 2022-2025 | |
| Pfizer INC. | $1,475.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $282.61 | 2023-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $249.93 | 2023-2025 | Erleada, Rybrevant, Imbruvica |
| Merck Sharp & Dohme LLC | $243.04 | 2023-2025 | Keytruda, Lynparza |
| Abbvie INC. | $207.42 | 2024-2025 | |
| Incyte Corporation | $183.60 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $154.11 | 2024-2025 | Zejula, Jemperli |
| Array Biopharma INC | $134.51 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $133.30 | 2024-2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2023-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $127.77 | 2024-2025 | Venclexta, Gazyva, Polivy |
| Tempus Ai, INC | $121.76 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals Lp | $118.14 | 2024-2025 | Imfinzi |
| Intera Oncology, INC | $114.21 | 2024 | Intera |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $106.59 | 2024-2025 | Orserdu |
| Celgene Corporation | $105.89 | 2023-2024 | Pomalyst, Opdualag |
| Taiho Oncology, INC. | $100.85 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $99.58 | 2024-2025 | Libtayo |
| Gilead Sciences, INC. | $84.20 | 2021-2024 | |
| Eisai INC. | $70.67 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $62.71 | 2025 | |
| Sumitomo Pharma America, INC. | $44.60 | 2025 | Orgovyx |
| Adc Therapeutics America, INC. | $33.59 | 2025 | |
| Legend Biotech USA INC. | $32.82 | 2025 | Carvykti |
| Genmab U.S., INC. | $30.65 | 2025 | Epkinly |
| Sobi, INC | $25.72 | 2025 | |
| Genzyme Corporation | $22.37 | 2025 | |
| Astellas Pharma US INC | $21.83 | 2025 | Vyloy |
| Lilly USA, LLC | $18.63 | 2024 | Retevmo, Jaypirca, Verzenio |
| Acrotech Biopharma INC. | $14.90 | 2025 | Beleodaq |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wallmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.